Dedicated to transforming the care of people living with rare genetic diseases of obesity
Mike and Tysen, father and son living with MC4R Pathway Heterozygous Obesity
Joan, wife to Mike and mother to Tysen, both diagnosed with MC4R Pathway Heterozygous Obesity
Leigha, living with Alström syndrome
Breezy, mother of Leigha, diagnosed with Alström syndrome
Solomon and Adalissa, siblings living with Bardet-Biedl syndrome
Olivia, Mother of Adalissa and Solomon, both diagnosed with Bardet Biedl syndrome
Joan, wife to Mike and mother to Tysen, both diagnosed with MC4R Pathway Heterozygous Obesity
Breezy, mother of Leigha, diagnosed with Alström syndrome
Olivia, Mother of Adalissa and Solomon, both diagnosed with Bardet Biedl syndrome
We’re focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger.
By targeting the MC4R pathway, we aim to develop therapeutics
for rare genetic diseases of obesity, including:
Proopiomelanocortin | Leptin Receptor (LEPR) | Bardet-Biedl |
Alström | POMC or LEPR | Smith-Magenis |
SRC1 Deficiency | MC4R Deficiency | SH2B1 Deficiency |
